CMMB Q3 2023 Earnings — Chemomab Therapeutics Ltd. Revenue & Financial Results | Market Cap Arena

CMMBChemomab Therapeutics Ltd.

$12M

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$18,938

Operating Income

-$4M

Net Income

-$4M

EPS (Diluted)

$-1.38

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$5M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$23M

Total Liabilities

$5M

Stockholders' Equity

$18M

Cash & Equivalents

$9M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$18,938	-$8M	+99.8%
Operating Income	-$4M	-$8M	+47.5%
Net Income	-$4M	-$8M	+51.1%